EVEREST MEDICINES
云 顶 新 耀

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of the Company dated 11 December 2025 (the "**Announcement**") in relation to the continuing connected transactions in relation to the Commercialization Service Agreement. Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the "**Circular**") containing, among other things, (a) details of the Commercialization Service Agreement; (b) the recommendations from the Independent Board Committee to the Independent Shareholders; (c) the letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders; and (d) a notice convening the EGM is expected to be despatched to the Shareholders on or before 16 January 2026.

As additional time is required for the Company to prepare and finalise the information to be included in the Circular, it is expected that the Circular will be published on or before 4 February 2026.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 16 January 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.